Question

A 32-year-old woman with relapsing-remitting multiple sclerosis presents with a positive Lhermitte sign indicating cervical cord involvement. She has low JC virus antibody titers and wishes to conceive in the future. Which of the following disease-modifying therapies is most appropriate for her?

• A. Fingolimod
• B. Interferon gamma
• C. Natalizumab
• D. Teriflunomide

Hint:

For MS and pregnancy: First-line safe drugs include Glatiramer acetate and Interferon-beta. For highly active disease requiring escalation, Natalizumab is considered relatively safe during early pregnancy. Teriflunomide and Fingolimod are strict contraindications due to severe teratogenicity.

Answer 1

The Correct Option is C

Concept:
A female patient of childbearing age with highly active relapsing-remitting multiple sclerosis (RRMS) is actively planning for future pregnancy. Her active disease is clinically evidenced by a positive Lhermitte sign (an electrical shock sensation radiating down the spine upon neck flexion, indicating active cervical cord demyelinating plaques).
The clinical challenge is to select a highly effective disease-modifying therapy (DMT) that adequately controls her aggressive spinal cord disease while remaining safely compatible with conception and pregnancy.
Explanation:
• Managing Multiple Sclerosis in women who wish to conceive requires a delicate balance between preventing devastating neurological relapses and minimizing teratogenic fetal exposure.

• Teriflunomide (Option D) is an oral pyrimidine synthesis inhibitor that is strictly contraindicated in pregnancy (Category X). It has a very long half-life, is a known potent teratogen, and requires an accelerated elimination protocol before any attempt at conception.

• Fingolimod (Option A) is a sphingosine-1-phosphate receptor modulator. It is also contraindicated during pregnancy due to significant teratogenic risks. Furthermore, if Fingolimod is stopped abruptly for pregnancy planning, patients are at a severe risk for massive, catastrophic rebound MS disease activity.

• Interferon gamma (Option B) is physiologically a pro-inflammatory cytokine and naturally exacerbates MS; it is absolutely not used for treatment. (Interferon-beta is the correct therapeutic class, which is safe in pregnancy but often insufficiently potent for highly active spinal cord disease).

• Natalizumab (Option C) is a highly potent humanized monoclonal antibody targeting alpha-4 integrin, preventing leukocyte transmigration across the blood-brain barrier. It is exceptionally effective for highly active RRMS.

• According to modern neurological guidelines, Natalizumab is widely considered to have a favorable safety profile regarding teratogenicity. In patients with highly active disease, it is frequently continued throughout conception and into the second trimester to prevent devastating rebound relapses.

• The explicit mention of her having "low JC virus antibody titers" further strongly supports the selection of Natalizumab, as this significantly minimizes the risk of developing Progressive Multifocal Leukoencephalopathy (PML), which is the drug's most feared opportunistic complication.
Final Answer:
Natalizumab is the most appropriate, highly effective disease-modifying therapy for a patient with active RRMS planning to conceive, provided her JC virus index remains low.